Page last updated: 2024-08-21

quinazolines and ritonavir

quinazolines has been researched along with ritonavir in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Beumer, JH; Christner, SM; Gramignoli, R; Parise, RA; Pillai, VC; Rudek, MA; Strom, SC; Venkataramanan, R	1
Bertulis, J; Brand, T; Gansser, D; Giessmann, T; Hocke, J; Jungnik, A; Marzin, K; Stopfer, P; Wind, S	1
Anders, NM; Beumer, JH; Deeken, JF; Rudek, MA; Rusnak, M; Wanjiku, T	1

Trials

1 trial(s) available for quinazolines and ritonavir

Article	Year
Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir. Clinical drug investigation, 2014, Volume: 34, Issue:3 Topics: Adolescent; Adult; Afatinib; Cross-Over Studies; Drug Combinations; Drug Interactions; Humans; Male; Middle Aged; Quinazolines; Rifampin; Ritonavir; Young Adult	2014

Other Studies

2 other study(ies) available for quinazolines and ritonavir

Article	Year
Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer. Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:10 Topics: 14-alpha Demethylase Inhibitors; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Erlotinib Hydrochloride; Female; Half-Life; Hepatocytes; HIV Infections; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Neoplasms; Nucleic Acid Synthesis Inhibitors; Quinazolines; Rifampin; Ritonavir	2013
Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib. Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:4 Topics: Administration, Oral; Alkynes; Animals; Anti-Retroviral Agents; Antineoplastic Agents; Benzoxazines; Biological Availability; Biotransformation; Cyclopropanes; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Dexamethasone; Drug Evaluation, Preclinical; Drug Interactions; Erlotinib Hydrochloride; Half-Life; Ketoconazole; Male; Metabolic Clearance Rate; Mice, Inbred Strains; Protein Kinase Inhibitors; Quinazolines; Ritonavir	2015

Article

Year

Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.

Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:10

Topics: 14-alpha Demethylase Inhibitors; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Erlotinib Hydrochloride; Female; Half-Life; Hepatocytes; HIV Infections; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Neoplasms; Nucleic Acid Synthesis Inhibitors; Quinazolines; Rifampin; Ritonavir

2013

Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.

Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:4

Topics: Administration, Oral; Alkynes; Animals; Anti-Retroviral Agents; Antineoplastic Agents; Benzoxazines; Biological Availability; Biotransformation; Cyclopropanes; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Dexamethasone; Drug Evaluation, Preclinical; Drug Interactions; Erlotinib Hydrochloride; Half-Life; Ketoconazole; Male; Metabolic Clearance Rate; Mice, Inbred Strains; Protein Kinase Inhibitors; Quinazolines; Ritonavir

2015